Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Current Deferred Revenue (2025)

Verrica Pharmaceuticals (VRCA) has 1 years of Current Deferred Revenue data on record, last reported at $782000.0 in Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $782000.0; the TTM value through Dec 2025 reached $782000.0, changed N/A, while the annual FY2025 figure was $782000.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $782000.0 in Q4 2025 per VRCA's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.6 million in Q3 2025 and bottomed at $481000.0 in Q2 2025.